244 related articles for article (PubMed ID: 10912577)
1. Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer.
Murren JR; Peccerillo K; DiStasio SA; Li X; Leffert JJ; Pizzorno G; Burtness BA; McKeon A; Cheng Y
Cancer Chemother Pharmacol; 2000; 46(1):43-50. PubMed ID: 10912577
[TBL] [Abstract][Full Text] [Related]
2. A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.
Hotta K; Ueoka H; Kiura K; Tabata M; Kuyama S; Satoh K; Kozuki T; Hisamoto A; Hosokawa S; Fujiwara K; Tanimoto M
Lung Cancer; 2004 Jul; 45(1):77-84. PubMed ID: 15196737
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity.
Adjei AA; Klein CE; Kastrissios H; Goldberg RM; Alberts SR; Pitot HC; Sloan JA; Reid JM; Hanson LJ; Atherton P; Rubin J; Erlichman C
J Clin Oncol; 2000 Mar; 18(5):1116-23. PubMed ID: 10694565
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.
Saltz LB; Spriggs D; Schaaf LJ; Schwartz GK; Ilson D; Kemeny N; Kanowitz J; Steger C; Eng M; Albanese P; Semple D; Hanover CK; Elfring GL; Miller LL; Kelsen D
J Clin Oncol; 1998 Dec; 16(12):3858-65. PubMed ID: 9850031
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
Choong NW; Vokes EE; Haraf DJ; Tothy PK; Ferguson MK; Kasza K; Rudin CM; Hoffman PC; Krauss SA; Szeto L; Mauer AM
J Thorac Oncol; 2008 Jan; 3(1):59-67. PubMed ID: 18166842
[TBL] [Abstract][Full Text] [Related]
6. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
Falcone A; Di Paolo A; Masi G; Allegrini G; Danesi R; Lencioni M; Pfanner E; Comis S; Del Tacca M; Conte P
J Clin Oncol; 2001 Aug; 19(15):3456-62. PubMed ID: 11481350
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks.
Rothenberg ML; Kuhn JG; Schaaf LJ; Rodriguez GI; Eckhardt SG; Villalona-Calero MA; Rinaldi DA; Hammond LA; Hodges S; Sharma A; Elfring GL; Petit RG; Locker PK; Miller LL; von Hoff DD
Ann Oncol; 2001 Nov; 12(11):1631-41. PubMed ID: 11822765
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors.
Couteau C; Risse ML; Ducreux M; Lefresne-Soulas F; Riva A; Lebecq A; Ruffié P; Rougier P; Lokiec F; Bruno R; Armand JP
J Clin Oncol; 2000 Oct; 18(20):3545-52. PubMed ID: 11032597
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer.
Bleickardt E; Argiris A; Rich R; Blum K; McKeon A; Tara H; Zelterman D; Burtness B; Davies MJ; Murren JR
Cancer Biol Ther; 2002; 1(6):646-51. PubMed ID: 12642688
[TBL] [Abstract][Full Text] [Related]
10. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer.
Murren JR; Anderson S; Fedele J; Pizzorno G; Belliveau D; Zelterman D; Burtness BA; Tocino I; Flynn SD; Beidler D; Cheng YC
J Clin Oncol; 1997 Jan; 15(1):148-57. PubMed ID: 8996136
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.
de Jonge MJ; Sparreboom A; Planting AS; van der Burg ME; de Boer-Dennert MM; ter Steeg J; Jacques C; Verweij J
J Clin Oncol; 2000 Jan; 18(1):187-94. PubMed ID: 10623709
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
Briasoulis E; Golfinopoulos V; Karina M; Papakostas P; Pavlidis N; Fountzilas G
Anticancer Drugs; 2010 Sep; 21(8):785-9. PubMed ID: 20647930
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.
Saltz LB; Kanowitz J; Kemeny NE; Schaaf L; Spriggs D; Staton BA; Berkery R; Steger C; Eng M; Dietz A; Locker P; Kelsen DP
J Clin Oncol; 1996 Nov; 14(11):2959-67. PubMed ID: 8918493
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S
Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer.
Tew WP; Radovich D; O'Reilly E; Schwartz G; Schrag D; Saltz LB; Kelsen DP; Kepler S; Ilson DH
Invest New Drugs; 2009 Aug; 27(4):366-73. PubMed ID: 18956138
[TBL] [Abstract][Full Text] [Related]
16. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
Rea DW; Nortier JW; Ten Bokkel Huinink WW; Falk S; Richel DJ; Maughan T; Groenewegen G; Smit JM; Steven N; Bakker JM; Semiond D; Kerr DJ; Punt CJ
Ann Oncol; 2005 Jul; 16(7):1123-32. PubMed ID: 15939714
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
18. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin.
de Jonge MJ; Verweij J; de Bruijn P; Brouwer E; Mathijssen RH; van Alphen RJ; de Boer-Dennert MM; Vernillet L; Jacques C; Sparreboom A
J Clin Oncol; 2000 Jan; 18(1):195-203. PubMed ID: 10623710
[TBL] [Abstract][Full Text] [Related]
20. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin.
Kudoh S; Fukuoka M; Masuda N; Yoshikawa A; Kusunoki Y; Matsui K; Negoro S; Takifuji N; Nakagawa K; Hirashima T
Jpn J Cancer Res; 1995 Apr; 86(4):406-13. PubMed ID: 7775263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
